Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAURA2: adjuvant osimertinib versus placebo after complete resection in EGFR-mutant stage IA2-IA3 non-small cell lung cancer
CTR20220984Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Osimertinib with Placebo (2 arms). Primary endpoint: Disease-free survival in the high-risk population. Started Aug 2022; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20220984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220984.